Case reportStaging of Burkitt's lymphoma and response to treatment monitored by pet scanning
References (10)
On the origin of cancer cells
Science
(1956)- et al.
Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-d-glucose: Correlation with CT
Radiology
(1994) - et al.
The use of FDG-PET in the detection and management of malignant lymphoma: Correlation of uptake with prognosis
J Nucl Med
(1991) - et al.
Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18-fluoro-deoxyglucose
J Nucl Med
(1988) - et al.
Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography
J Nucl Med
(1991)
Cited by (26)
<sup>18</sup>F-FDG PET and PET/CT in Burkitt's lymphoma
2010, European Journal of RadiologyCitation Excerpt :There is only limited data available on the role of FDG PET–PET/CT in other histologies [5,6] including the Burkitt's lymphomas. Barrington et al. [7] demonstrated in 1995 a case of a 32-year-old Burkitt's lymphoma patient that had a staging FDG PET-only scan demonstrating intense uptake in multiple extranodal areas, including bone marrow, bowel and peritoneum. Six days after the commencement of chemotherapy a repeat PET scan was negative.
Burkitt's lymphoma with leptomeningeal metastasis: Demonstration by FDG-PET and MRI
2009, European Journal of Radiology ExtraCitation Excerpt :PET is a functional imaging technique that provides dynamic information on cellular metabolism. Fluorodeoxyglucose positron emission tomography (FDG-PET) is an imaging modality using the physiological tracer glucose (modified as 18-fluorine-2-fluorodeoxyglucose), whose uptake and metabolism is increased in malignant cells [5]. FDG studies make use of this property of malignant cells to help identify areas of increased metabolism, indirectly locating areas of metastases.
Applications of PET/CT in Pediatric Patients with Fever of Unknown Origin
2008, PET ClinicsCitation Excerpt :FDG has been shown to accumulate in non-Hodgkin's and Hodgkin's lymphomas. Furthermore, FDG uptake is greater in the higher-grade lymphomas.149–154 The incremental value of FDG-PET is the ability to demonstrate active disease sites that cannot be detected with other imaging modalities.155–158
Imaging in staging of malignant lymphoma: A systematic review
2008, BloodCitation Excerpt :Imaging of malignant lymphoma with FDG was first described in 1987,18 and the first reports on FDG-PET as a whole-body staging method in malignant lymphoma appeared in the 1990s.19 TTTTTT–22 PET technology has improved dramatically since its development. Initial patient imaging units had a system resolution greater than 15 mm, whereas current units have a 4 to 5 mm resolution.6
PET and PET/CT in Pediatric Oncology
2007, Seminars in Nuclear MedicineCitation Excerpt :For nearly 2 decades, this was the best functional imaging agent available for the evaluation of lymphomas. FDG-PET has several features that make it preferable to 67Ga citrate scintigraphy, including a shorter injection to imaging interval, completion of the study in a few hours instead of multiple days, higher image quality, and more favorable dosimetry (Table 2) In numerous studies that predominantly included adult patients, FDG has been shown to accumulate in non-Hodgkin’s and Hodgkin’s lymphomas.41,102-125 Similar to Gallium-67 citrate, FDG uptake generally is greater in the higher-grade lymphomas than in lower-grade lymphomas.109,111
PET in pediatric diseases
2005, Radiologic Clinics of North America